Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NASDAQ: RVPH · IEX Real-Time Price · USD
3.84
0.00 (0.13%)
At close: Dec 1, 2023, 4:00 PM
3.80
-0.04 (-0.91%)
After-hours: Dec 1, 2023, 7:50 PM EST
0.13%
Market Cap 107.07M
Revenue (ttm) n/a
Net Income (ttm) -37.65M
Shares Out 27.92M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 229,690
Open 3.99
Previous Close 3.83
Day's Range 3.78 - 3.99
52-Week Range 3.03 - 9.25
Beta 0.04
Analysts Strong Buy
Price Target 16.75 (+336.77%)
Earnings Date Nov 14, 2023

About RVPH

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention"d... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 10
Stock Exchange NASDAQ
Ticker Symbol RVPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for RVPH stock is "Strong Buy." The 12-month stock price forecast is $16.75, which is an increase of 336.77% from the latest price.

Price Target
$16.75
(336.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

3 days ago - GlobeNewsWire

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

13 days ago - GlobeNewsWire

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

17 days ago - GlobeNewsWire

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with ...

19 days ago - GlobeNewsWire

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study.

4 weeks ago - Reuters

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total scor...

4 weeks ago - GlobeNewsWire

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resou...

Other symbols: ARECSTSS
2 months ago - Accesswire

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...

2 months ago - GlobeNewsWire

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChi...

2 months ago - Accesswire

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...

3 months ago - GlobeNewsWire

Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension ...

3 months ago - GlobeNewsWire

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 -

3 months ago - GlobeNewsWire

RedChip Launches 'Small Stocks, Big Money' Podcast

New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm speci...

Other symbols: BFRGLTRNSTSSZOM
4 months ago - Accesswire

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August

CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that...

4 months ago - GlobeNewsWire

Reviva Pharmaceuticals to be Added to Russell Microcap® Index

CUPERTINO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that...

5 months ago - GlobeNewsWire

Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms...

5 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June

CUPERTINO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that...

6 months ago - GlobeNewsWire

Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF)

6 months ago - GlobeNewsWire

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

Data reinforce brilaroxazine's differentiated clinical pharmacology and safety profile Brilaroxazine may be co-administered with other drugs metabolized by CYP3A inhibitors Metabolism and excretion pr...

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

CUPERTINO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023

CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...

7 months ago - GlobeNewsWire

Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-...

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...

7 months ago - GlobeNewsWire